×
Indication
×
BLINCYTO® (blinatumomab) is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.
This site is intended for US health care professionals only.
Indication
BLINCYTO® (blinatumomab) for injection 35 mcg single-use vial
PACKAGE CONTENTS AND STORAGE
BLINCYTO® (blinatumomab) PACKAGE CONTENTS AND VIALS
BLINCYTO® (blinatumomab) Package Contents and Vials
Package and vials are not actual size
Each BLINCYTO® package contains1:
  • One BLINCYTO® 35 mcg single-use vial containing a sterile, preservative free, white to off-white lyophilized powder

  • One IV Solution Stabilizer 10 mL single-use glass vial containing a sterile, preservative free, colorless-to-slightly yellow, clear solution

  • Do not use the IV Solution Stabilizer to reconstitute BLINCYTO®

Please see full Prescribing Information for complete reconstitution and preparation instructions.

STORAGE AND HANDLING OF BLINCYTO® AND IV SOLUTION
STABILIZER (IVSS) VIALS
BLINCYTO® (blinatumomab) Storage Instructions

Refrigerate at 2°C to 8°C (36°F to 46°F) in the original packaging.1

BLINCYTO® (blinatumomab) Storage Instructions

Do not freeze.1

BLINCYTO® (blinatumomab) Storage Instructions

Protect the vials of
BLINCYTO® and IVSS
from light until time
of use.1



Please see full Prescribing Information for complete Storage and Handling requirements, including those for reconstituted BLINCYTO® and IV Solution Stabilizer.

Back to Top
Reference:
  1. BLINCYTO® (blinatumomab) Prescribing Information, Amgen.